Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ELVN Stock Forecast 2026-2027
$42.36
Current Price
$2.58B
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ELVN Price Targets
+88.9%
To High Target of $80.00
+41.6%
To Median Target of $60.00
+6.2%
To Low Target of $45.00
ELVN Price Momentum
+17.3%
1 Week Change
+2.5%
1 Month Change
+83.5%
1 Year Change
+175.1%
Year-to-Date Change
-12.7%
From 52W High of $48.53
+186.5%
From 52W Low of $14.79
📊 TOP ANALYST CALLS
Did ELVN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Enliven is one of their latest high-conviction picks.
Latest ELVN Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, ELVN has a bullish consensus with a median price target of $60.00 (ranging from $45.00 to $80.00). The overall analyst rating is Strong Buy (10.0/10). Currently trading at $42.36, the median forecast implies a 41.6% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ELVN Analyst Ratings
10
Buy
0
Hold
0
Sell
ELVN Price Target Range
Low
$45.00
Average
$60.00
High
$80.00
Current: $42.36
Latest ELVN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ELVN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jun 9, 2026 | Stifel | Dara Azar | Buy | Initiates | $60.00 |
| Jun 2, 2026 | Mizuho | Salim Syed | Outperform | Maintains | $62.00 |
| May 8, 2026 | Goldman Sachs | Buy | Maintains | $N/A | |
| Mar 26, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 25, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Jul 2, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 16, 2025 | Goldman Sachs | Buy | Initiates | $N/A | |
| Jun 16, 2025 | Baird | Outperform | Maintains | $N/A | |
| May 16, 2025 | Jones Trading | Buy | Maintains | $N/A | |
| May 15, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 21, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 13, 2024 | BTIG | Buy | Initiates | $N/A | |
| Nov 15, 2024 | Baird | Outperform | Maintains | $N/A | |
| Oct 31, 2024 | Jones Trading | Buy | Initiates | $N/A | |
| Oct 1, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Sep 9, 2024 | HC Wainwright & Co. | Buy | Initiates | $N/A | |
| Jun 11, 2024 | Baird | Outperform | Initiates | $N/A | |
| Apr 9, 2024 | Mizuho | Buy | Initiates | $N/A | |
| Mar 29, 2023 | Jefferies | Buy | Initiates | $N/A | |
| Mar 3, 2023 | TD Cowen | Outperform | Initiates | $N/A |
Enliven Therapeutics, Inc. (ELVN) Competitors
The following stocks are similar to Enliven based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ELVN
Enliven Therapeutics
mkt cap
2.81B
Enliven Therapeutics, Inc. (ELVN) Financial Data
Enliven Therapeutics, Inc. has a market capitalization of $2.58B with a P/E ratio of -23.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -26.6%.
Valuation Metrics
Market Cap
$2.58B
Enterprise Value
$2.36B
P/E Ratio
-23.1x
PEG Ratio
0.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+17.5%
Current Ratio
40.3x
Debt/Equity
0.1x
ROE
-26.6%
ROA
-18.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Enliven Therapeutics, Inc. (ELVN) Business Model
About Enliven Therapeutics, Inc.
What They Do
Develops targeted therapies for precision medicine.
Business Model
The company generates revenue by researching and developing novel therapeutic solutions for specific diseases, particularly focusing on genetic disorders and oncology. By leveraging advanced technology and innovative methodologies, it aims to create personalized treatments that meet unmet medical needs, potentially leading to significant market opportunities.
Additional Information
Enliven Therapeutics is positioned within the biotechnology sector, attracting investor interest due to the transformative potential of its personalized healthcare solutions. Its commitment to improving patient care and outcomes aligns with the growing demand for precision medicine in the pharmaceutical and healthcare industries.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
61
CEO
Mr. Richard A. Fair M.B.A.
Country
United States
IPO Year
2023
Website
www.enliventherapeutics.comEnliven Therapeutics, Inc. (ELVN) Latest News & Analysis
Latest News
Quick Summary
Enliven Therapeutics closed an upsized public offering of 10.5 million shares at $37.50 each, including pre-funded warrants for 1.7 million shares at $37.499 each.
Why It Matters
Enliven Therapeutics raised significant capital through a public offering, enhancing liquidity and funding for development projects, which may positively impact future growth and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Enliven Therapeutics (ELVN) announced updated Phase 1 ENABLE trial data for ELVN-001, focusing on its treatment in previously treated chronic myeloid leukemia patients.
Why It Matters
Updated trial data for ELVN-001 could indicate potential advancements in treatment efficacy for chronic myeloid leukemia, impacting Enliven Therapeutics' market position and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Enliven Therapeutics reported positive Phase 1b results for ELVN-001 in chronic myeloid leukemia, with 61% overall MMR and a median treatment duration of 35 weeks. Phase 3 trial expected to start in H2 2026.
Why It Matters
Positive trial results for ELVN-001 indicate strong efficacy and safety in CML patients. FDA alignment for Phase 3 boosts confidence in the drug's potential, likely influencing stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
4 days ago
Quick Summary
Enliven Therapeutics (Nasdaq: ELVN) has launched a $250 million underwritten public offering of common stock and pre-funded warrants to investors.
Why It Matters
Enliven Therapeutics' $250 million stock offering indicates potential dilution of shares, impacting existing shareholder value and signaling the company's capital needs for growth or operations.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Enliven Therapeutics has priced an upsized public offering of 8,933,334 shares at $37.50 each and 1,733,333 pre-funded warrants at $37.499, aimed at raising capital.
Why It Matters
Enliven Therapeutics' public offering at $37.50 per share indicates strong investor interest, impacting stock liquidity and potential future valuation. The option for pre-funded warrants adds flexibility for investors.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Top Wall Street analysts have updated their outlook on several key companies. For detailed ratings changes, visit the analyst ratings page for upgrades and downgrades.
Why It Matters
Analyst outlook changes can significantly impact stock prices, influencing investor sentiment and trading strategies based on perceived growth or risk.
Source: Benzinga
Market Sentiment:
Positive
Frequently Asked Questions About ELVN Stock
What is Enliven Therapeutics, Inc.'s (ELVN) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Enliven Therapeutics, Inc. (ELVN) has a median price target of $60.00. The highest price target is $80.00 and the lowest is $45.00.
Is ELVN stock a good investment in 2026?
According to current analyst ratings, ELVN has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $42.36. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ELVN stock?
Wall Street analysts predict ELVN stock could reach $60.00 in the next 12 months. This represents a 41.6% increase from the current price of $42.36. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Enliven Therapeutics, Inc.'s business model?
The company generates revenue by researching and developing novel therapeutic solutions for specific diseases, particularly focusing on genetic disorders and oncology. By leveraging advanced technology and innovative methodologies, it aims to create personalized treatments that meet unmet medical needs, potentially leading to significant market opportunities.
What is the highest forecasted price for ELVN Enliven Therapeutics, Inc.?
The highest price target for ELVN is $80.00 from at , which represents a 88.9% increase from the current price of $42.36.
What is the lowest forecasted price for ELVN Enliven Therapeutics, Inc.?
The lowest price target for ELVN is $45.00 from at , which represents a 6.2% increase from the current price of $42.36.
What is the overall ELVN consensus from analysts for Enliven Therapeutics, Inc.?
The overall analyst consensus for ELVN is bullish. Out of 3 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $60.00.
How accurate are ELVN stock price projections?
Stock price projections, including those for Enliven Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 5:08 AM UTC